
Source briefing
Sex differences in trajectories to cardio-renal and mental health outcomes following the onset of type 2 diabetes: An observational cohort study using multi-state analysis in the UK Clinical Practice Research Datalink
by Fabiola Eto, Miriam Samuel, Daniel Stow, Rafael Henkin, Alisha Angdembe, Michael R. Barnes, Sarah Finer, Rohini Mathur Background Type 2 diabetes (T2D) presents a significant global health challenge, and its prevalence is expected to rise. T2D is…
Read →
Source briefing
Frequency and prognostic outcomes of emergency diagnosis in 13 non-neoplastic conditions in England: A population-based cohort study using linked electronic health records of 1.7 million patients
by Emma Whitfield, Becky White, Matthew E. Barclay, Meena Rafiq, Nadine Zakkak, Marta Berglund, Hardeep Singh, Sean McPhail, Spiros Denaxas, Georgios Lyratzopoulos Background In patients with cancer, diagnosis through or soon after the use of emergency hospital care…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Akynzeo, netupitant,palonosetron, Date of authorisation: 27/05/2015, Revision: 23, Status: Authorised
Human medicines European public assessment report (EPAR): Akynzeo, netupitant,palonosetron, Date of authorisation: 27/05/2015, Revision: 23, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Ablymico, liraglutide, Date of authorisation: 15/07/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Ablymico, liraglutide, Date of authorisation: 15/07/2026, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Hopledo, levodopa,carbidopa, Date of authorisation: 20/08/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Hopledo, levodopa,carbidopa, Date of authorisation: 20/08/2026, Status: Authorised
Read →
Source briefing
Kazakhstan’s Election Brings a New Parliament — and More Pressure on Journalists
President Kassym-Jomart Tokayev’s allies dominated the vote as independent observers raised concerns over a campaign marked by restrictions on critical voices.
Read →
Source briefing
Trends of stillbirth, early neonatal and perinatal mortality rates and sociodemographic differentials of perinatal mortality rates in 17 low- and middle-income countries: A modeling study
by Mohamed M. Ali, Luca Cegolon, Saverio Bellizzi Background Stillbirths and early neonatal deaths account for a substantial proportion of global child mortality. Reliable measurement of these outcomes remains challenging in settings where civil registration systems are incomplete…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised
Read →
Source briefing
Ross Levine on Blood Cancer, Cancer Genetics, and New Therapies
Ross L. Levine, MD, Chief Scientific Officer at Memorial Sloan Kettering Cancer Center, joins The Future of Medicine for a conversation about blood cancer, cancer genetics, and how a laboratory discovery can eventually lead to new treatments.More than…
Read →